Search research articles

关于 JoVE

概览领导团队博客 JoVE 帮助中心

作者

出版流程编辑委员会范围与政策同行评审常见问题投稿

图书馆员

用户评价订阅访问资源图书馆顾问委员会常见问题

研究

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments 存档

教育

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual 教师资源中心教师网站

使用条款与条件

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序

Same author

Generative Replica Exchange: A Flow-Based Framework for Accelerating Replica-Exchange Simulations.

Journal of chemical theory and computation·2026

Same author

Large-Scale Profiling of Kinase Degradation by Using Norbornene-Based Hydrophobic Tag (HyT) Strategy.

Angewandte Chemie (International ed. in English)·2026

Same author

Indel pattern-guided repair mapping reveals genome-wide DNA repair networks in CRISPR/Cas9 editing.

Nucleic acids research·2026

Same author

Discovery of a Potent RXRγ Degrader WCF-598 for the Treatment of Castration-Resistant Prostate Cancer.

Journal of medicinal chemistry·2026

Same author

Peritumoural adipose tissue promotes ferroptosis resistance by 3-hydroxykynurenine-mediated suppression of ferritinophagy.

Nature cell biology·2026

Same author

Structure-Based Design of 4-(1-Methyl-1<i>H</i>-indol-3-yl)pyrimidin-2-amine Derivatives as the First Covalent FGFR3 Selective Inhibitors.

Journal of medicinal chemistry·2026

Search research articles

相关实验视频

Updated: Jan 13, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

基于结构的虚拟查发现了具有抗癌活性强大的PLK1抑制剂.

Qian Zhang¹, Wenxin Zhu¹, Yi Cai¹

¹School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China.

Journal of chemical information and modeling

|January 6, 2026

概括

研究人员使用计算实验方法确定了用于癌症治疗的强有力的PLK1抑制剂. 化合物BDE30671203具有很高的选择性,并诱导癌细胞循环停止和亡.

更多相关视频

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening

A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening

Published on: May 12, 2017

相关实验视频

Last Updated: Jan 13, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening

A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening

Published on: May 12, 2017

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
计算生物学计算生物学

背景情况:

波罗样酶1 (PLK1) 是细胞循环进展的关键调节剂,也是癌症治疗的有希望的标.
开发选择性PLK1抑制剂对于有效的癌症治疗至关重要.

研究的目的:

通过结合计算和实验策略,识别和验证新的选择性PLK1抑制剂.
评估已识别的抑制剂在癌细胞中的抗增殖和机械效应.

主要方法:

利用了一个管道,包括酶支架优先级,基于结构的对接,分子动力学 (MD) 模拟.
进行了体外生化和细胞分析,包括抗增殖,细胞循环停止和亡研究.
对AURKA和AURKB等相关激酶进行了激酶选择性分析.

主要成果:

确定了BDE30671203和PB4767006058,它们与PLK1.1具有强烈的结合亲和力.
BDE30671203在七个癌细胞系中显示出强大的PLK1抑制 (IC50 = 2.163 ± 0.401 nM) 和显著的抗增殖作用 (IC50 < 10 μM).
BDE30671203诱导了G2/M停止和亡,降低了关键细胞循环调节器和Bcl-2的调节,并表现出高选择性 (>450倍AURKA,>1200倍AURKB).

结论:

这项研究为PLK1向癌症药物发现提供了有前途的化学起点.
一个强大的计算实验选策略用于酶抑制剂的发现得到了验证.
BDE30671203是一种具有治疗潜力的高度选择性的PLK1抑制剂.